English   español  
Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/164710
COMPARTIR / IMPACTO:
Estadísticas
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:
Título

Effects of aripiprazole, quetiapine and ziprasidone on plasma prolactin levels in individuals with first episode nonaffective psychosis: Analysis of a randomized open-label 1 year study

AutorCrespo-Facorro, Benedicto; Ortiz-Garcia de la Foz, Victor; Valdizán, Elsa M. ; Pérez-Iglesias, Rocío; Ayesa-Arriola, Rosa
Fecha de publicación2017
EditorElsevier
CitaciónSchizophrenia Research 189: 134-141 (2017)
Resumen[Rationale]: Hyperprolactinemia is considered a troubling adverse effect of antipsychotics. Direct comparisons among second generation antipsychotics are scant in clinical practice. We hypothesize prolactin-sparing second-generation antipsychotics may have differential effects on prolactin levels and that they may be influenced by sex. [Objectives]: To explore the differential effect of three widely used prolactin-sparing antipsychotics, aripiprazole, quetiapine and ziprasidone, on prolactin plasma levels in first episode non-affective psychosis during a 1 year of treatment. [Method]: From October 2005 to January 2011 a prospective, randomized, open-label study was undertaken. 141 patients who were randomly allocated to aripiprazole (N = 56), quetiapine (N = 36) or ziprasidone (N = 49) were analyzed. The main outcome was differences in prolactin plasma levels over 1 year follow-up among the three antipsychotics. Prolactin levels had a skewed distribution and therefore they were log-transformed before statistical analyses. [Results]: Male patients on aripiprazole had a lower risk of suffering an increase on prolactin plasma levels (N = 71; F = 12.645; p < 0.001). There was a gender effect with smaller changes in mean prolactin values only in males. Aripiprazole had a reduced risk of hyperprolactinemia (aripiprazole 19.6%) compared to quetiapine (44.4%) and ziprasidone (32.7%) (p = 0.038); and quite similar findings were found when investigating males (p = 0.040). No significant differences were found in females. The percentages of mild prolactin excess were: 14.3% on aripiprazole, 36.1% on quetiapine and 18.4% on ziprasidone (χ = 6.611 p = 0.037). [Conclusions]: Our findings provide additional evidence of differential effects of three sparing-prolactin antipsychotics on prolactin release and may help clinicians to decide among therapeutic options.
DescripciónCrespo-Facorro, Benedicto et al.
URIhttp://hdl.handle.net/10261/164710
Identificadoresdoi: 10.1016/j.schres.2017.01.046
e-issn: 1573-2509
issn: 0920-9964
Aparece en las colecciones: (IBBTEC) Artículos
Ficheros en este ítem:
Fichero Descripción Tamaño Formato  
accesoRestringido.pdf15,38 kBAdobe PDFVista previa
Visualizar/Abrir
Mostrar el registro completo
 

Artículos relacionados:


NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.